Brodimoprim
Code | Size | Price |
---|
TAR-T19858-25mg | 25mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19858-50mg | 50mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19858-1mg | 1mg | £139.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19858-5mg | 5mg | £201.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T19858-10mg | 10mg | £262.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Brodimoprim is an inhibitor of dihydrofolate reductase(DHFR). Brodimoprim is also a long-acting broad-spectrum antibacterial agent characterized by a good pharmacokinetic profile.
CAS:
56518-41-3
Formula:
C13H15BrN4O2
Molecular Weight:
339.193
Pathway:
DNA Damage/DNA Repair; Cell Cycle/Checkpoint; Microbiology/Virology; Metabolism
Purity:
0.98
SMILES:
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1Br
Target:
DHFR; Antibacterial
References
1. De Campora E, Radici M, Camaioni A. Efficacy and tolerability of brodimoprim in otitis. J Chemother. 1993 Dec;5(6):529-31.
2. Scaglione F, et al. Efficacy and tolerability of brodimoprim od versus norfloxacin bid in the treatment of bacterial urinary tract infections. Int J Clin Pharmacol Res. 1995;15(3):121-5.
3. Caira MR, et al. Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim. J Pharm Sci. 2007 May;96(5):996-1007.
4. Braga PC, et al. Influence of brodimoprim on polymorphonuclear leukocyte phagocytosis and oxidant radical production. Chemotherapy. 1995 Sep-Oct;41(5):360-7.